Ingevity Corp (NGVT) stock
NGVTNYSEChemicals & Allied ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3076% above fair value
$58.31−0.97 (-1.64%)
Close on Nov 18, 2026Market cap $2.00BP/E 39.7Yield –
Ingevity operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ingevity's operating income for the twelve months ending Dec 31, 2024 was $425.90M, up 0.6% year over year. For fiscal 2025 it was $418.70M, down 1.7% from the year before. Over ten years it grew 9.7% a year on average. The highest annual figure on record is $452.60M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $418.70M | -1.7% |
| FY2024 | Dec 31, 2024 | $425.90M | +0.6% |
| FY2023 | Dec 31, 2023 | $423.20M | -6.5% |
| FY2022 | Dec 31, 2022 | $452.60M | +7.2% |
| FY2021 | Dec 31, 2021 | $422.20M | +6.1% |
| FY2020 | Dec 31, 2020 | $397.90M | +0.3% |
| FY2019 | Dec 31, 2019 | $396.90M | +23.8% |
| FY2018 | Dec 31, 2018 | $320.50M | +32.1% |
| FY2017 | Dec 31, 2017 | $242.70M | +48.3% |
| FY2016 | Dec 31, 2016 | $163.60M | -1.6% |
| FY2015 | Dec 31, 2015 | $166.30M | -22.0% |
| FY2014 | Dec 31, 2014 | $213.30M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $137.50M | +55.9% |
| Q3 FY2024 | Sep 30, 2024 | $110.20M | -0.2% |
| Q2 FY2024 | Jun 30, 2024 | $101.30M | -16.1% |
| Q1 FY2024 | Mar 31, 2024 | $76.90M | -26.0% |
| Q4 FY2023 | Dec 31, 2023 | $88.20M | +18.7% |
| Q3 FY2023 | Sep 30, 2023 | $110.40M | -20.1% |
| Q2 FY2023 | Jun 30, 2023 | $120.70M | -0.3% |
| Q1 FY2023 | Mar 31, 2023 | $103.90M | -12.7% |
| Q4 FY2022 | Dec 31, 2022 | $74.30M | -6.7% |
| Q3 FY2022 | Sep 30, 2022 | $138.20M | +15.6% |
| Q2 FY2022 | Jun 30, 2022 | $121.10M | +2.9% |
| Q1 FY2022 | Mar 31, 2022 | $119.00M | +12.9% |
| Q4 FY2021 | Dec 31, 2021 | $79.60M | -28.2% |
| Q3 FY2021 | Sep 30, 2021 | $119.50M | -6.3% |
| Q2 FY2021 | Jun 30, 2021 | $117.70M | +75.1% |
| Q1 FY2021 | Mar 31, 2021 | $105.40M | +14.3% |
| Q4 FY2020 | Dec 31, 2020 | $110.90M | +21.7% |
| Q3 FY2020 | Sep 30, 2020 | $127.60M | +11.9% |
| Q2 FY2020 | Jun 30, 2020 | $67.20M | -38.0% |
| Q1 FY2020 | Mar 31, 2020 | $92.20M | +10.4% |
| Q4 FY2019 | Dec 31, 2019 | $91.10M | +24.3% |
| Q3 FY2019 | Sep 30, 2019 | $114.00M | +25.7% |
| Q2 FY2019 | Jun 30, 2019 | $108.30M | +21.1% |
| Q1 FY2019 | Mar 31, 2019 | $83.50M | +24.4% |
| Q4 FY2018 | Dec 31, 2018 | $73.30M | -11.7% |
| Q3 FY2018 | Sep 30, 2018 | $90.70M | +44.7% |
| Q2 FY2018 | Jun 30, 2018 | $89.40M | +56.6% |
| Q1 FY2018 | Mar 31, 2018 | $67.10M | +68.2% |
| Q4 FY2017 | Dec 31, 2017 | $83.00M | +224.2% |
| Q3 FY2017 | Sep 30, 2017 | $62.70M | +26.7% |
| Q2 FY2017 | Jun 30, 2017 | $57.10M | – |
| Q1 FY2017 | Mar 31, 2017 | $39.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $25.60M | – |
| Q3 FY2016 | Sep 30, 2016 | $49.50M | – |
See a number that looks wrong?